CCLG-ALL-2008方案治疗不同危险度儿童B系急性淋巴细胞白血病耐受性和有效性分析  

Tolerance and efficacy of CCLG-ALL-2008 regimen in the treatment of B-line acute lymphoblastic leukemia in children with different risk-stratification

作　　者：鲍亮 吴南海 潘虹宇 员菡子 BAO Liang;WU Nanhai;PAN Hongyu;YUAN Hanzi(Pediatric Department,Sixth Medical Center of PLA General Hospital,Beijing 100048,China)

机构地区：[1]中国人民解放军总医院第六医学中心儿科,北京100048

出　　处：《中国小儿血液与肿瘤杂志》2022年第3期193-196,共4页Journal of China Pediatric Blood and Cancer

摘　　要：目的探究CCLG-ALL-2008方案治疗不同危险程度儿童B系急性淋巴细胞白血病(B-ALL)的耐受性和有效性。方法选取2016年2月—2018年2月在我院接受CCLG-ALL-2008方案治疗的100例B-ALL患儿,根据患儿初诊危险度及治疗过程中阶段评估的结方法选取2016年2月—2018年2月在我院接受CCLG-ALL-2008方案治疗的100例B-ALL患儿,根据患儿初诊危险度及治疗过程中阶段评估的结果,确定最终危险度。标危(SR)49例,中危(MR)23例和高危(HR)28例。比较各组治疗期间并发症发生率、临床疗效、微小残留病变情况、3年总生存率、无事件生存率。结果HR组和MR组患儿治疗期间并发症发生率显著高于SR组,MR组显著高于SR组,差异有统计学意义(P<0.05);HR组和MR组CR率显著低于SR组,复发率、死亡率显著高于SR组,HR组CR率显著低于MR组,复发率、死亡率显著高于MR组,差异有统计学意义(P<0.05);第33天和第12周MR组和HR组MRD<10^(-4)患儿比例均显著低于SR组,HR组显著低于MR组,差异有统计学意义(P<0.05);SR组和MR组患儿3年OS、3年EFS显著高于HR组,SR组显著高于MR组,差异有统计学意义(P<0.05)。结论CCLG-ALL-2008方案能够有效治疗B-ALL患儿,但不同危险度患儿中其应用效果具有一定的差异,危险分度越高,患儿的耐受性和有效性越差,值得临床参考。Objective To investigate the tolerability and efficacy of CCLG-ALL-2008 protocol in the treatment of B-line ALL(B-ALL)in children with different risk-stratification.Methods 100 children with B-ALL who received CCLG-ALL-2008 in our hospital from February 2016 to February 2018 were selected according to risk of initial diagnosis and stage assessment during treatment..There were 49 cases of standard risk(SR),23 cases of moderate risk(MR)and 28 cases of high risk(HR).The incidence of complications,clinical efficacy,minimal residual disease(MRD),3-year overall survival(OS)and event free survival(EFS)were compared.Results The incidence of complications in HR group and MR group was significantly higher than that in SR group,and that in MR group was significantly higher than that in SR group(P<0.05);The CR rate in HR group and MR group was significantly lower than that in SR group,the recurrence rate and death rate were significantly higher than those in SR group,the CR rate in HR group was significantly lower than that in MR group,and the recurrence rate and death rate were significantly higher than those in MR group(P<0.05);At the 33rd day and 12th week,the proportion of children with MRD<10^(-4) in MR group and HR group was significantly lower than that in SR group,and that in HR group was significantly lower than that in MR group(P<0.05);The 3-year OS and 3-year EFS of children in SR group and MR group were significantly higher than those in HR group,and those in SR group were significantly higher than those in MR group(P<0.05).Conclusions CCLG-ALL-2008 regimen can effectively treat children with B-ALL,but there are certain differences in its application effect among children with different risk levels.The higher the risk score,the worse the tolerance and effectiveness of ALL children,which is worthy of clinical reference.

关 键 词：CCLG-ALL-2008方案 B系急性淋巴细胞白血病 儿童 危险分度 耐受性 有效性 

分 类 号：R733.71[医药卫生—肿瘤]